Detected ·
Flare Therapeutics
$85M—
Flare Therapeutics raised $85M in Series C led by Third Rock Ventures and Nextech Invest to advance FX-111, their lead candidate targeting androgen receptor signaling in prostate cancer, into Phase 1 clinical trials.
- Website
- www.flaretx.com
- Amount
- $85 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-02 20:03:54 UTC
- Signal ID
- 13a5b1f4-507f-408b-b2ee-1746945eda34
As the API returns it
{
"id": "13a5b1f4-507f-408b-b2ee-1746945eda34",
"created_at": "2026-07-02T20:03:54.079526Z",
"company_name": "Flare Therapeutics",
"company_website_url": "www.flaretx.com",
"company_linkedin_url": "https://www.linkedin.com/company/flare-therapeutics",
"event_type": "funding",
"funding_amount": 85000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Flare Therapeutics raised $85M in Series C led by Third Rock Ventures and Nextech Invest to advance FX-111, their lead candidate targeting androgen receptor signaling in prostate cancer, into Phase 1 clinical trials.*"
}